On the Journey to Support Drug Developers With End-to-End Outsourcing
MIKART SPONSORED CONTENT

On the Journey to Support Drug Developers With End-to-End Outsourcing

Mikart, an oral dosage focused contract development and manufacturing organization (CDMO), is moving beyond generic manufacturing to support customers from non-GMP preclinical work to full-scale GMP commercial volumes with a recently expanded range of capabilities, including formulation development, manufacturing, and serialized packaging. This article covers the ways in which customers benefit from its end-to-end service offering.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

  • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.